According to a recent LinkedIn post from F-Prime, the firm is highlighting the 2026 Breakthrough Prize in Life Sciences awarded to Katherine High, M.D., alongside collaborators Jean Bennett, M.D., Ph.D., and Albert Maguire, M.D. The post notes their work on a gene therapy for inherited retinal degeneration that became the first U.S. FDA‑approved gene therapy for a genetic disease and is described as paving the way for newer retinal treatments.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The same LinkedIn post emphasizes that F-Prime was an early investor in RhyGaze, where High serves as CEO, and suggests that the firm views her leadership as central to advancing next‑generation gene therapies. For investors, this points to F-Prime’s continued focus on high‑impact biotech platforms, particularly in ophthalmology and gene therapy, which could enhance the portfolio’s long‑term value if such therapies achieve broader clinical adoption and commercial traction.